{"id":7575,"date":"2019-01-04T06:33:02","date_gmt":"2019-01-04T06:33:02","guid":{"rendered":"https:\/\/www.nicox.com\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/"},"modified":"2019-01-04T06:33:02","modified_gmt":"2019-01-04T06:33:02","slug":"vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/","title":{"rendered":"VYZULTA approuv\u00e9 au Canada par le partenaire licenci\u00e9 de Nicox"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9 a re\u00e7u l\u2019approbation au Canada de VYZULTA<sup>TM<\/sup> (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%. Cette approbation a \u00e9t\u00e9 annonc\u00e9e hier par Bausch + Lomb, un leader mondial de la sant\u00e9 oculaire, filiale de Bausch Health Companies Inc. (NYSE\/TSX: BHC), et partenaire exclusif mondial de Nicox pour VYZULTA<sup>TM<\/sup>, indiqu\u00e9 pour la r\u00e9duction de la pression intraoculaire (PIO) chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire.<\/p>\n<p><strong>Michele Garufi, Pr\u00e9sident directeur g\u00e9n\u00e9ral de Nicox, a d\u00e9clar\u00e9<\/strong> : \u201c<em>L\u2019approbation de VYZULTA au Canada, premi\u00e8re approbation en dehors des Etats-Unis, est une excellente nouvelle et pose les jalons d\u2019une ann\u00e9e qui, selon nous, devrait \u00eatre importante pour Nicox. En 2019, nous pr\u00e9voyons pour ZERVIATE son lancement commercial aux \u00c9tats-Unis par notre partenaire Eyevance ainsi que de potentiels accords de licence suppl\u00e9mentaires dans d\u2019autres pays. Ainsi, avec les redevances provenant de l\u2019accord avec Bausch + Lomb pour VYZULTA et les futurs flux de redevances pour ZERVIATE, nous anticipons pour Nicox un revenu continu et progressif pour les prochaines ann\u00e9es.<\/em>\u201d<\/p>\n<p>Nicox re\u00e7oit des redevances nettes croissantes de 6% \u00e0 12% sur les ventes mondiales de VYZULTA<sup>TM<\/sup> ainsi que des paiements d\u2019\u00e9tape pouvant atteindre un montant de 150 millions de dollars net li\u00e9s aux ventes mondiales.<\/p>\n<p>Le communiqu\u00e9 de presse de Bausch + Lomb du 3 janvier 2019 portant sur cette approbation est disponible sur le lien <a href=\"https:\/\/www.newswire.ca\/news-releases\/bausch-lomb-announces-health-canada-approval-of-vyzulta-tm-latanoprostene-bunod-ophthalmic-solution-0-024-for-the-treatment-of-glaucoma-897268417.html\">https:\/\/www.newswire.ca\/news-releases\/bausch-lomb-announces-health-canada-approval-of-vyzulta-tm-latanoprostene-bunod-ophthalmic-solution-0-024-for-the-treatment-of-glaucoma-897268417.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9 a re\u00e7u l\u2019approbation au Canada de VYZULTATM (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%. Cette approbation a \u00e9t\u00e9 annonc\u00e9e hier par Bausch + Lomb, un leader mondial de la sant\u00e9 oculaire, filiale [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7575","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VYZULTA approuv\u00e9 au Canada par le partenaire licenci\u00e9 de Nicox - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VYZULTA approuv\u00e9 au Canada par le partenaire licenci\u00e9 de Nicox - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9 a re\u00e7u l\u2019approbation au Canada de VYZULTATM (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%. Cette approbation a \u00e9t\u00e9 annonc\u00e9e hier par Bausch + Lomb, un leader mondial de la sant\u00e9 oculaire, filiale [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-04T06:33:02+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"VYZULTA approuv\u00e9 au Canada par le partenaire licenci\u00e9 de Nicox\",\"datePublished\":\"2019-01-04T06:33:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\\\/\"},\"wordCount\":278,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\\\/\",\"name\":\"VYZULTA approuv\u00e9 au Canada par le partenaire licenci\u00e9 de Nicox - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2019-01-04T06:33:02+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VYZULTA approuv\u00e9 au Canada par le partenaire licenci\u00e9 de Nicox - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/","og_locale":"fr_FR","og_type":"article","og_title":"VYZULTA approuv\u00e9 au Canada par le partenaire licenci\u00e9 de Nicox - Nicox","og_description":"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9 a re\u00e7u l\u2019approbation au Canada de VYZULTATM (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%. Cette approbation a \u00e9t\u00e9 annonc\u00e9e hier par Bausch + Lomb, un leader mondial de la sant\u00e9 oculaire, filiale [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/","og_site_name":"Nicox","article_published_time":"2019-01-04T06:33:02+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/"},"author":{"name":"","@id":""},"headline":"VYZULTA approuv\u00e9 au Canada par le partenaire licenci\u00e9 de Nicox","datePublished":"2019-01-04T06:33:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/"},"wordCount":278,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/","url":"https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/","name":"VYZULTA approuv\u00e9 au Canada par le partenaire licenci\u00e9 de Nicox - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2019-01-04T06:33:02+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/vyzulta-approuve-au-canada-par-le-partenaire-licencie-de-nicox\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7575"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7575\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}